Home Cart Sign in  
Chemical Structure| 408303-43-5 Chemical Structure| 408303-43-5

Structure of GW 766994
CAS No.: 408303-43-5

Chemical Structure| 408303-43-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GW 766994 is a specific and oral chemokine receptor-3 (CCR3) antagonist, which has entered clinical trial for asthma and eosinophilic bronchitis.

Synonyms: GW 994

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GW 766994

CAS No. :408303-43-5
Formula : C21H24Cl2N4O3
M.W : 451.35
SMILES Code : O=C(N)C1=CC=C(CNC(NC[C@H]2CN(CC3=CC=C(Cl)C(Cl)=C3)CCO2)=O)C=C1
Synonyms :
GW 994
MDL No. :N/A

Safety of GW 766994

Related Pathways of GW 766994

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01160224 Asthma Phase 2 Completed - Canada, Alberta ... More >> GSK Investigational Site Calgary, Alberta, Canada, T2N 4Z6 Canada, Ontario GSK Investigational Site Hamilton, Ontario, Canada, L8N 4A6 Canada, Quebec GSK Investigational Site Montreal, Quebec, Canada, H2X 2P4 GSK Investigational Site Montreal, Quebec, Canada, H4J 1C5 Canada GSK Investigational Site Quebec, Canada, G1V 4G5 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.22mL

0.44mL

0.22mL

11.08mL

2.22mL

1.11mL

22.16mL

4.43mL

2.22mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories